Osimertinib Improves Overall Survival in EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Written by Sarah B. Goldberg MD, MPH

Read the full article here

Source: PracticeUpdate
Categories: General Medicine News, Latest Headlines
Tags: ,
Tweets with this article
PracticeUpdate
Osimertinib Improves Overall Survival in EGFR-Mutated #NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status | comment: Dr. Sarah Goldberg: https://t.co/fhvwf7ueNW @YaleCancer #lcsm

Related Articles